drugset / Trial / NCT05087342
Latino Semaglutide Study
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study to understand better how this anti-obesity medication works to assist individuals to lose weight and maintain weight loss. This study may lead to the development of other related medications for assisting people with the disease of obesity.
Timeline
- Start
- 2022-12-13
- Primary completion
- 2024-05-29
- Completion
- 2024-05-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Semaglutide | Peptide | 2.4 mg | Subcutaneous |